Gain Therapeutics, Inc. (GANX) Reports In-Line Q3 EPS

Gain Therapeutics, Inc. (NASDAQ: GANX) reported Q3 EPS of ($0.15), in-line with the analyst estimate of ($0.15).

For earnings history and earnings-related data on Gain Therapeutics, Inc. (GANX) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c